Z-WEHD-FMK: Irreversible Caspase-5 Inhibitor for Inflammation & Pathogenesis Research

Executive Summary: Z-WEHD-FMK (CAS 210345-00-9) is a peptide-based, cell-permeable, and irreversible inhibitor targeting inflammatory caspases, primarily caspase-1, -4, and -5, with proven efficacy in blocking pyroptosis and Chlamydia-induced Golgi fragmentation (Padia et al. 2025). The compound acts by covalently modifying active caspase cysteine residues, abrogating proteolytic activity in human cell models. Z-WEHD-FMK reduces Chlamydia trachomatis proliferation by inhibiting golgin-84 cleavage in infected HeLa cells, decreasing bacterial output by ~2 log units after 9 h at 80 μM (APExBIO). The inhibitor is insoluble in water but readily dissolves in DMSO or ethanol, and is stable at -20°C. These properties make Z-WEHD-FMK a robust tool for dissecting caspase-mediated events in inflammation, apoptosis, and host-pathogen interaction research.

Biological Rationale

Inflammatory caspases, including caspase-1, -4, and -5 (humans), orchestrate key signaling events in pyroptosis, a form of pro-inflammatory programmed cell death (Padia et al. 2025). Caspase-1 is essential for cleaving gasdermin D (GSDMD), leading to membrane pore formation and cell lysis. Non-canonical pyroptosis in humans involves caspase-4 and -5, which are directly activated by cytosolic lipopolysaccharide (LPS) from Gram-negative bacteria. These caspases also process interleukin-1β (IL-1β) and IL-18, amplifying inflammatory responses. Dysregulation of these pathways is implicated in infectious disease progression, cancer, and chronic inflammation (Decoding Inflammatory Caspases). Targeted inhibition provides mechanistic insight and potential therapeutic leverage.

Mechanism of Action of Z-WEHD-FMK

Z-WEHD-FMK is a synthetic tetrapeptide (Z-Trp-Glu(OMe)-His-Asp(OMe)-FMK) with a fluoromethyl ketone (FMK) reactive group. The FMK moiety forms an irreversible covalent bond with the active-site cysteine of caspase-1, -4, and -5, leading to permanent loss of enzymatic activity (APExBIO). The peptide backbone confers selectivity for inflammatory caspases over executioner caspases such as caspase-3 and -7 (Caspase-5 Inhibitor Dossier). Cell permeability allows Z-WEHD-FMK to access intracellular targets in live cell assays. By blocking caspase-driven proteolysis, Z-WEHD-FMK inhibits downstream events such as GSDMD cleavage, Golgi fragmentation, and cytokine maturation.

Evidence & Benchmarks

• Z-WEHD-FMK (80 μM, 9 h) prevents Chlamydia-induced cleavage of golgin-84 and reduces C. trachomatis infectious yield by ~100-fold in HeLa cells (APExBIO product page).
• Treatment with Z-WEHD-FMK abrogates caspase-1-dependent pyroptosis in cell lines, as demonstrated by suppression of GSDMD-mediated cell death upon inflammasome activation (Padia et al. 2025).
• Irreversible inhibition of caspase-5 activity by Z-WEHD-FMK is confirmed by in vitro cleavage assays using recombinant enzyme and peptide substrates (Z-WEHD-FMK: Irreversible Caspase Inhibitor).
• Z-WEHD-FMK blocks downstream cytokine maturation (e.g., IL-1β) in inflammasome-stimulated cell culture models (Advanced Irreversible Caspase Inhibitor).
• Compound is soluble in DMSO (≥46.33 mg/mL) and ethanol (≥26.32 mg/mL, ultrasonic assistance), but insoluble in aqueous buffers (APExBIO).

Applications, Limits & Misconceptions

Z-WEHD-FMK is widely used in:

• Dissecting caspase-1/4/5-dependent pyroptosis mechanisms in human and rodent cell models.
• Blocking Chlamydia-induced Golgi fragmentation and lipid trafficking disruption for pathogen-host studies (Caspase-5 Inhibitor Dossier).
• Inflammation research, including IL-1β maturation and cytokine release assays.
• Apoptosis and necroptosis discrimination assays (Decoding Irreversible Caspase Inhibition).

Compared to related articles, this analysis emphasizes quantitative benchmarks and workflow integration, building upon mechanistic reviews such as Decoding Inflammatory Caspases by providing direct experimental conditions and troubleshooting guidance.

Common Pitfalls or Misconceptions

• Does not inhibit apoptotic caspase-3/-7 at tested concentrations: Z-WEHD-FMK is optimized for inflammatory caspases, with minimal activity against executioner caspases.
• Not effective in murine models for caspase-11 inhibition: The peptide sequence is tailored to human caspase recognition sites.
• Insoluble in water: Direct addition to aqueous buffers leads to precipitation and loss of activity—use DMSO or ethanol stock solutions.
• Irreversible inhibition precludes rescue: Once administered, caspase function cannot be restored in treated cells or lysates.
• Long-term storage of solution stocks is discouraged: Degradation may occur; prepare fresh stocks for each experiment.

Workflow Integration & Parameters

Preparation: Dissolve Z-WEHD-FMK in DMSO (≥46.33 mg/mL) or ethanol (≥26.32 mg/mL, with sonication). Avoid water-based solvents. Aliquot and store at -20°C. Use freshly thawed solutions.

Experimental Use: For Chlamydia trachomatis-infected HeLa cells, treat with 80 μM Z-WEHD-FMK for 9 hours at 37°C. For pyroptosis inhibition, pre-treat cells 30–60 min before inflammasome activation. Dose and timing may require optimization based on cell type and endpoint.

Controls: Include vehicle (DMSO/ethanol) controls and, where possible, alternative caspase inhibitors to confirm specificity.

Readouts: Assess Golgi integrity by immunofluorescence, bacterial output by plaque assay, and cytokine processing by ELISA or immunoblot.

For additional workflow insights, see the Z-WEHD-FMK: Irreversible Caspase Inhibitor dossier, which we extend here by providing updated solubility and storage parameters.

Conclusion & Outlook

Z-WEHD-FMK, supplied by APExBIO, remains a gold-standard irreversible inhibitor for dissecting inflammatory caspase signaling. Robust experimental benchmarks support its adoption in studies of pyroptosis, Chlamydia pathogenesis, and cytokine biology. While not suited for apoptotic caspases or murine-specific targets, Z-WEHD-FMK's precision and reproducibility underpin its value for inflammation and infectious disease research. Ongoing studies leveraging tools like Z-WEHD-FMK are expected to refine our understanding of caspase biology and therapeutic intervention strategies.